Here are the DEF 14A proxy statements from Zevra Therapeutics, Inc. (ZVRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ZVRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZVRA filings page.
Zevra Therapeutics, Inc. is asking stockholders to elect two Class II directors, ratify Ernst & Young LLP as auditor for 2026, and approve phasing out its classified Board so all directors stand for annual elections beginning with the 2029 meeting.
The company highlights 2025 net revenue of $106.5 million, including $87.4 million from MIPLYFFA for Niemann-Pick disease type C, and GAAP diluted EPS of $1.35. Management reports more than 40% penetration of diagnosed U.S. NPC patients, 161 MIPLYFFA enrollment forms, and an Expanded Access Program serving 113 global patients.
Zevra also notes sale of a Rare Pediatric Disease Priority Review Voucher for $150 million, repayment of its term loan, and relocation of its headquarters to Boston. The Board emphasizes its largely independent composition, committee structure, and policies such as a clawback and prohibition on short-selling company stock.